文献速递艾滋病与性传播感染

多替拉韦每日一次对比达芦那韦联合考比司他在成人原发性HIV-1感染时的疗效:OPTIPRIM2-ANRS 169随机开放标签3期试验

Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

在原发性HIV-1感染成人中开展的随机开放标签多中心3期试验,比较多替拉韦与达芦那韦/考比司他方案。主要终点第48周外周血单核细胞总HIV-1 DNA水平经基线校正后两组无显著差异(P=0.52),多替拉韦组早期病毒学抑制比例更高。作者认为多替拉韦方案是主要的一线选择。

要点

  • 第48周HIV-1 DNA下降中位数多替拉韦组-1.48、达芦那韦/考比司他组-1.39 log10 copies/million PBMCs(P=0.52)。
  • 第4、8、12周HIV-1 RNA<50 copies/mL比例多替拉韦组分别为24%、55%、67%,达芦那韦/考比司他组为0%、2%、17%。
  • 第48周HIV-1 RNA<50 copies/mL比例多替拉韦组94% vs 达芦那韦/考比司他组90%。

核心结论

  • 在原发性HIV-1感染期间启动基于多替拉韦或基于达芦那韦的方案均强烈且相似地降低血液储存库大小。
  • 考虑到在高HIV-1传播风险期快速病毒抑制,基于多替拉韦的方案是主要的一线选择。

研究设计与样本

  • OPTIPRIM2-ANRS 169为随机(1:1)、开放标签、多中心试验,纳入成人原发性HIV-1感染者。
  • 入组条件为最近10天内western blot或immunoblot检测分别≤5或≤3条HIV抗体。
  • 2017年4月至2018年8月期间从31家医院纳入101例患者。
  • 主要终点为第48周外周血单核细胞总HIV-1 DNA水平(经基线水平校正)。
  • 主要次要终点为HIV-1 RNA水平下降。

主要发现

  • 多数患者为男性(93%),中位年龄36岁,17%为Fiebig分期≤3期。
  • 基线血浆HIV-1 RNA和DNA中位数(IQR)分别为5.8(5.0-6.6)和3.87(3.52-4.15)log10 copies/million PBMCs。
  • 第48周HIV-1 DNA下降中位数(IQR)多替拉韦组为-1.48(-1.74至-1.06)、达芦那韦/考比司他组为-1.39(-1.55至-0.98)log10 copies/million PBMCs(P=0.52)。
  • 血浆HIV-1 RNA<50 copies/mL比例多替拉韦组 vs 达芦那韦/考比司他组:第4周24% vs 0%,第8周55% vs 2%,第12周67% vs 17%,第48周94% vs 90%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether integrase strand transfer inhibitors (INSTIs) can decrease HIV-1 DNA levels more rapidly than boosted PIs during primary HIV-1 infection (PHI) is unknown. We hypothesized that once-daily dolutegravir/tenofovir/emtricitabine could reduce the viral reservoir through rapid viral replication control further than once-daily darunavir/cobicistat/tenofovir/emtricitabine. METHODS: The OPTIPRIM2-ANRS 169 study was a randomized (1:1), open-label, multicentre trial in adults with ≤5 or ≤3 HIV antibodies detected, respectively, by western blot or immunoblot in the last 10 days. The primary endpoint was total HIV-1 DNA levels in PBMCs at Week 48 (W48) adjusted for baseline levels. The main secondary endpoint was HIV-1 RNA level decrease. RESULTS: Between April 2017 and August 2018, 101 patients were included from 31 hospitals. Most patients were men (93%), the median age was 36 years and 17% were Fiebig stage ≤3. The median (IQR) plasma HIV-1 RNA and DNA levels were, respectively, 5.8 (5.0-6.6) and 3.87 (3.52-4.15) log10 copies/million PBMCs. The median (IQR) decreases in HIV-1 DNA levels at W48 were -1.48 (-1.74 to -1.06) and -1.39 (-1.55 to -0.98) log10 copies/million PBMCs in the dolutegravir and darunavir/cobicistat groups, respectively (P = 0.52). Plasma HIV-1 RNA levels were <50 copies/mL in 24% versus 0% of patients in the dolutegravir and darunavir/cobicistat groups at W4, 55% versus 2% at W8, 67% versus 17% at W12, and 94% versus 90% at W48, respectively. CONCLUSIONS: Dolutegravir-based and darunavir-based regimens initiated during PHI strongly and similarly decreased the blood reservoir size. Considering the rapid viral suppression during a period of high HIV-1 transmission risk, dolutegravir-based regimens are a major first-line option.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chéret A, Bauer R, Meiffrédy V, et al. Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial. J Antimicrob Chemother. 2022. PMID: 35762503. doi:10.1093/jac/dkac207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。